US pharmaceutical company Merck has reported a major development in the clinical trial of its experimental drug Remigromig for diabetic macular edema, a diabetes-related eye condition that can cause vision loss.
US pharmaceutical company Merck has reported a major development in the clinical trial of its experimental drug Remigromig for diabetic macular edema, a diabetes-related eye condition that can cause vision loss.